Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Flecainide acetate was administered at a dose of 100 mg twice daily to 15 patients with drug-resistant ventricular ectopy. Eleven patients had evidence of organic heart disease. Left ventricular function was normal in 13 patients, and 2 patients had mild and moderate left ventricular dysfunction respectively. All patients underwent a control (off drugs) and a flecainide Holter ECG. Flecainide suppressed ventricular ectopy by greater than 70% in 13 patients (86.6%), suppressed bigeminal beats by greater than 90% in 13 (86.6%), suppressed ventricular couplets by greater than 90% in 12 of 14 patients (85.7%), and completely suppressed runs of nonsustained ventricular tachycardia in 6 of 9 patients (66.6%). In only one patient who showed a 69% suppression of ventricular ectopy did ventricular couplets increase. No side effects of the drug were noted. We conclude that flecainide at a dose of 100 mg twice daily is highly effective in suppressing ventricular ectopy that is resistant to other anti-arrhythmic agents.
 ...
PMID:Oral flecainide for the treatment of drug-resistant ventricular ectopy. 169 48

Flecainide acetate (Flecaine) is a new antiarrhythmic which has recently become available; its efficacity in treatment of ventricular rhythm disorders has been amply demonstrated. In this study we have evaluated its efficacity per os in treatment of auricular rhythm disorders refractory to the usual therapies, and its effects on the accessory routes of atrioventricular conduction. The results are very promising and better than those obtained with amiodarone in auricular disorders. They show that flecainide is a drug of importance among therapeutic agents used in treatment of auricular arrhythmia, and its action on Kent's bundle makes it a drug of choice in management of Wolff-Parkinson-White syndrome, especially as it seems equally efficacious in its action on the accessory routes with a short refractory period. Most of our patients did not present organic cardiopathy and the side-effects were generally benign. A non-negligible number of cases of paroxysmal hypertension were noted, in disagreement with literature data, and this point needs to be clarified by further study.
 ...
PMID:[Value of flecainide in supraventricular arrhythmias]. 374 Jul 79

Flecainide acetate is a powerful antiarrhythmic initially used to treat ventricular arrhythmias. Despite an excess mortality in this indication and in the presence of heart disease, flecainide remains a good antiarrhythmic for supraventricular tachycardias in a healthy heart.
 ...
PMID:[Flecainide acetate]. 876 46

Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as maintenance of sinus rhythm in patients with atrial fibrillation and/or supraventricular tachycardias. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is not recommended in patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations. We herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronary artery disease.
...
PMID:Flecainide: Current status and perspectives in arrhythmia management. 2571 55